Genomic Health Inc. (NASDAQ:GHDX) shares shot up 4.7% during mid-day trading on Monday . The stock traded as high as $30.57 and last traded at $30.38, with a volume of 78,457 shares traded. The stock had previously closed at $29.03.

Several brokerages recently issued reports on GHDX. Canaccord Genuity restated a “buy” rating on shares of Genomic Health in a research report on Thursday, May 5th. Leerink Swann restated a “buy” rating on shares of Genomic Health in a research report on Thursday, May 26th. Finally, Zacks Investment Research upgraded Genomic Health from a “sell” rating to a “hold” rating in a research report on Wednesday, July 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. Genomic Health presently has an average rating of “Hold” and a consensus price target of $33.50.

The company has a 50 day moving average of $27.17 and a 200-day moving average of $26.78. The stock’s market capitalization is $959.09 million.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, hitting the consensus estimate of ($0.18). The firm earned $81.97 million during the quarter, compared to the consensus estimate of $81.27 million. Genomic Health’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.29) EPS. Equities analysts anticipate that Genomic Health Inc. will post ($0.45) earnings per share for the current fiscal year.

In other news, insider Phillip G. Febbo sold 6,324 shares of the stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $27.20, for a total value of $172,012.80. Following the completion of the transaction, the insider now directly owns 15,113 shares in the company, valued at $411,073.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO G Bradley Cole sold 5,000 shares of the stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $27.60, for a total transaction of $138,000.00. Following the completion of the transaction, the chief operating officer now owns 39,970 shares of the company’s stock, valued at $1,103,172. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently bought and sold shares of GHDX. Marshall Wace LLP bought a new position in Genomic Health during the fourth quarter valued at about $6,097,000. Russell Frank Co boosted its position in Genomic Health by 327.4% in the fourth quarter. Russell Frank Co now owns 99,754 shares of the company’s stock valued at $3,517,000 after buying an additional 76,416 shares during the period. Royce & Associates LLC boosted its position in Genomic Health by 90.0% in the fourth quarter. Royce & Associates LLC now owns 66,500 shares of the company’s stock valued at $2,341,000 after buying an additional 31,500 shares during the period. California State Teachers Retirement System boosted its position in Genomic Health by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 32,989 shares of the company’s stock valued at $1,161,000 after buying an additional 600 shares during the period. Finally, ProShare Advisors LLC boosted its position in Genomic Health by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 28,759 shares of the company’s stock valued at $1,012,000 after buying an additional 2,287 shares during the period.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.